No, patients do not need to hold their daily low-dose aspirin for trigger point injections in the back.
Trigger point injections are low-risk superficial procedures that do not require discontinuation of aspirin therapy. The bleeding risk associated with these injections is minimal and does not justify the cardiovascular and cerebrovascular risks that come with stopping aspirin, particularly in patients taking it for secondary prevention.
Risk Stratification Framework
The key distinction here is understanding procedural bleeding risk:
- Low-risk procedures (trigger point injections, peripheral joint injections, superficial injections): Continue aspirin
- Intermediate-risk procedures (epidural steroid injections, facet injections): Requires shared decision-making
- High-risk procedures (spinal cord stimulator placement, intrathecal pump placement): Consider holding aspirin
Trigger point injections fall into the low-risk category because they:
- Are performed in muscle tissue, not near neuraxial structures
- Involve superficial needle placement
- Have compressible injection sites
- Carry minimal risk of catastrophic bleeding complications
Evidence Supporting Continuation
A large retrospective study of 2,204 spine procedures found that continuing aspirin during low-to-intermediate risk procedures resulted in only one minor bleeding complication (injection site bleeding) among 467 patients who continued anticoagulation 1. Importantly, this single complication occurred during a radiofrequency ablation (a higher-risk procedure than trigger point injection) in a patient on dual antiplatelet therapy.
The cardiovascular guidelines consistently emphasize that aspirin should be "continued indefinitely" in patients with established cardiovascular disease 2, 3, 4. The risk of thrombotic events from aspirin discontinuation—including myocardial infarction and stroke—substantially outweighs the minimal bleeding risk from trigger point injections.
Critical Distinction from Neuraxial Procedures
While one case report documented an epidural hematoma following an interlaminar epidural injection in a patient on aspirin 5, this involved a neuraxial procedure with potential for catastrophic spinal cord compression—a completely different risk profile than superficial trigger point injections. The American Society of Regional Anesthesia (ASRA) guidelines appropriately distinguish between these procedure types.
Common Pitfalls to Avoid
- Do not conflate trigger point injections with epidural or spinal procedures: The bleeding risk profiles are fundamentally different
- Do not routinely hold aspirin for low-risk procedures: The thrombotic risk from discontinuation exceeds the bleeding risk
- Recognize that aspirin for secondary prevention (post-MI, post-stroke) carries higher thrombotic risk if stopped: One analysis showed absolute risk increases of 1.83-2.02% for cardiovascular events within 30 days of stopping antiplatelet therapy 6
Practical Approach
For patients on daily low-dose aspirin (81-100 mg) undergoing trigger point injections:
- Continue aspirin without interruption
- Document the decision and rationale
- Ensure adequate local hemostasis with direct pressure post-injection
- Monitor the injection site briefly before discharge
The only scenario requiring consideration of aspirin discontinuation would be if the patient has a known bleeding disorder or is on multiple antithrombotic agents (aspirin plus clopidogrel, aspirin plus anticoagulation), which would warrant individualized risk assessment—but even then, for trigger point injections specifically, continuation is generally safe 1.